Ion Beam Applications SA (IBAB) Earnings Call Transcripts

Ion Beam Applications SA's Latest Earnings Call - March 27, 2026

In the fiscal year 2025, Ion Beam Applications SA (IBA) reported record revenue of EUR 620 million, marking a significant increase of EUR 122 million from the previous year. Adjusted EBIT reached EUR 27.4 million, surpassing guidance and reflecting a profitability improvement of EUR 10 million year-on-year. Management has confirmed guidance for fiscal year 2026, projecting adjusted EBIT of at least EUR 32 million, supported by a record backlog of EUR 1.6 billion and strong order intake in Proton Therapy and Nuclear Medicine. The company is transitioning towards a more consistently profitable model, with a focus on scaling service activities and improving margins.

Reported metrics

Guidance from management

Management has confirmed guidance for 2026, projecting adjusted EBIT of at least EUR 32 million, supported by a strong backlog and improved operational efficiency.

What management said

Thank you very much to the audience for listening to our results presentation. For information, you will find on this presentation the key dates from our financial calendar. We will now move on to the Q&A session. [Operator Instructions]. We will start with Frank Claassen. So you should be able to speak, Frank. Frank, we cannot hear you, or maybe we can start with David. He was the second in line.

When it comes to Dosimetry, we took -- we have implemented actually a number of cost reduction measures, productivity measure to adjust to the vision we had on the market development while preserving the sustainability through continued R&D investment. And the short answer to your question is yes, we can expect to see profitability improvement in Dosimetry already in 2026.

What analysts pressed on

Analysts expressed concerns regarding the future profitability of the Dosimetry segment and the impact of bad debt on financial performance. There were also questions about the sustainability of margins in the competitive Proton Therapy market.

Main topics on the call

• Record Revenue and Profitability — IBA achieved record revenue of EUR 620 million in 2025, an increase of 24% year-on-year, and adjusted EBIT of EUR 27.4 million, exceeding previous guidance. CEO Olivier Legrain stated, "We delivered on our commitments. O...
• Strong Order Backlog — The company reported a record backlog of EUR 1.6 billion, driven by a 40% increase in equipment order intake, particularly in Proton Therapy. Legrain noted, "Our growth engine has also strengthened with a record backlog....
• Proton Therapy Turnaround — Proton Therapy returned to profitability with an adjusted EBIT contribution of EUR 10.2 million, a significant turnaround from a negative contribution of EUR 12 million in 2024. This was attributed to strong equipment sa...
• Guidance for 2026 — Management has provided guidance for 2026, projecting adjusted EBIT of at least EUR 32 million. CFO Catherine Vandenborre emphasized, "We reiterate our confidence in IBA's profitability trajectory while being mindful of ...

Read the full Ion Beam Applications SA transcript (March 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 15 Ion Beam Applications SA earnings call transcripts on record, spanning March 26, 2020 to March 27, 2026. Based on this history, Ion Beam Applications SA reports semi-annually. The most recent call on file is dated March 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IBAB

Exchange

ENXTBR

Country

BE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

15

First call

March 26, 2020

Most recent

March 27, 2026

Reporting cadence

semi-annually